newsfilter
← Latest News
GlobeNewswire·

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA